Product Datasheet

BN-104

Catalog No. **BP-00867** · CAS **2938995-50-5** · Form **free base** · Physical state **solid** · Color **white to off-white** · Version **1.0** · Revision **2026-09-14**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
Epigenetic Reader Domain; Potassium Channel	**Cancer**

Molecular formula	$C_{31}H_{35}FN_8O_2$
Molecular weight	**570.6604**

STRUCTURE



DESCRIPTION

BN-104 (BNM-1192) can inhibit the Menin-MLL interaction and can be used in cancer research, such as acute myeloid leukemia.

BIOLOGICAL ACTIVITY

In Vitro

Zefamenib (BN-104) inhibits the proliferation of leukemia cells, with IC50 values of: MV-4-11 AF4 fusion (3.5 nM); MOLM13 AF9 fusion (12 nM); OCI-AML3 NPM1 mutant (11 nM).

Zefamenib (10 μM, 0-24 h) causes degradation of Menin protein in MV-4-11 cells.

In Vivo

Zefamenib (BN-104) (0-60 mg/kg, oral, twice a day, 21 days) inhibits tumor proliferation in a mouse model.

SOLUBILITY

Soluble in DMSO

REFERENCES

[1].Carbonyl substituted diazaspiro compounds and its use Assignee: BioNova Pharmaceuticals (Shanghai) Limited World Intellectual Property Organization, WO2023098876 A1